G
GRIN Therapeutics
Developing potent therapies for neurological and psychiatric disorders with a focus on negative allosteric modulators
About GRIN Therapeutics
GRIN Therapeutics, Inc. is a biotechnology company focused on developing advanced therapies for neurological and psychiatric disorders. Operating in the pharmaceutical and healthcare sectors, the company targets conditions such as FCD Type II, a rare neurodevelopmental disorder. GRIN Therapeutics leverages its expertise in negative allosteric modulators to create potent investigational drugs like radiprodil, which has received Priority Medicine PRIME designation from the European Medicines Agency. The company's business model revolves around research and development, aiming to bring effective treatments to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of successful therapies and potential partnerships with other pharmaceutical entities. GRIN Therapeutics serves a global market, addressing unmet medical needs and providing solutions for patients with complex neurological conditions.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | May 2025 | $140M | $560M | Blackstone · Angelini Pharma | ↗ |
Growth signals
Latest recorded traffic for GRIN Therapeutics is 2.1K monthly website visits, up 0% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
GRIN Therapeutics in the New York City ecosystem
The GRIN Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Blackstone
Angelini Pharma
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GRIN Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GRIN Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







